Law360, New York (May 22, 2012, 8:36 PM ET) -- A Delaware federal judge on Friday barred Mylan Pharmaceuticals Inc. from selling a generic version of Galderma Laboratories Inc.'s rosacea drug Oracea, even though the patent Mylan was found to have infringed was issued after its generic received government approval.
Judge Leonard P. Stark, who found Mylan liable for infringement in August, ordered the U.S. Food and Drug Administration to withdraw its approval for Mylan's abbreviated new drug application and permanently enjoined the generic version until Galderma's patent expires in 2027.
Mylan argued that it was...
Judge Bars Mylan's Oracea Generic In Galderma IP Case
To view the full article, take a free trial now.
